gross profit bridgeinconsistent2021-12-31
Withheld: gross profit could not be reconciled with the rest of this filer’s statement.
Revenue
$677.56M
Fiscal year ended 2025-12-31Operating income
$77.22M
Fiscal year ended 2025-12-31Free cash flow
$136.42M
Fiscal year ended 2025-12-31Kiniksa Pharmaceuticals International, plc (KNSA) reported revenue of $677.56M and net income of $59.00M for the fiscal year ended 2025-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Kiniksa Pharmaceuticals International, plc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $677.56M | $423.24M | $270.26M | $220.18M | $38.54M |
| Cost of revenue | $77.67M | $60.91M | $33.41M | $22.90M | $9.10M |
| Gross profit | $599.89M | $362.33M | $236.85M | $197.28M | Unavailable |
| Operating income | $77.22M | -$45.62M | -$25.20M | $9.77M | -$156.64M |
| Net income | $59.00M | -$43.19M | $14.08M | $183.36M | -$157.92M |
| Research & development | $96.85M | $111.62M | $76.10M | $65.49M | $99.30M |
| Weighted-average diluted shares | shares 78.98M | shares 71.42M | shares 71.92M | shares 70.42M | shares 68.58M |
| Pretax income | $88.87M | -$36.15M | -$16.65M | $11.03M | -$156.54M |
| Income tax expense | $29.86M | $7.04M | -$30.74M | -$172.34M | $1.38M |
| Diluted EPS | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 |
| Selling, general & administrative | $196.27M | $168.01M | $129.43M | $97.95M | $85.95M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cash & equivalents | $165.60M | $183.58M | $107.95M | $122.72M | $122.47M |
| Total assets | $763.63M | $580.55M | $526.32M | $459.67M | $232.80M |
| Current assets | $527.18M | $331.80M | $276.30M | $243.06M | $196.45M |
| Total liabilities | $196.03M | $142.12M | $87.48M | $63.52M | $47.76M |
| Current liabilities | $139.18M | $100.62M | $63.67M | $47.07M | $44.82M |
| Total equity incl. NCI | $567.61M | $438.44M | $438.84M | $396.15M | $185.04M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $54.90M | $26.36M | $31.12M | $21.60M | $3.68M |
| Accounts receivable | $15.59M | $41.72M | $21.27M | $12.66M | $3.98M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $2.03M | $2.04M | $8.25M | $7.90M | $1.87M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating cash flow | $137.98M | $25.69M | $13.30M | $5.81M | -$126.30M |
| Capital expenditures | $1.57M | $277.00K | $130.00K | $105.00K | $415.00K |
| Investing cash flow | -$188.99M | $37.67M | -$29.56M | -$8.08M | $128.64M |
| Financing cash flow | $33.02M | $12.27M | $1.50M | $2.52M | $5.88M |
| Net change in cash | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Stock-based compensation | $37.00M | $30.69M | $27.15M | $25.12M | $25.17M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $1.55M | $1.70M | $2.34M | $2.40M | $2.36M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free cash flow | $136.42M | $25.41M | $13.17M | $5.70M | -$126.71M |
| Gross margin | 88.5% | 85.6% | 87.6% | 89.6% | Unavailable |
| Operating margin | 11.4% | -10.8% | -9.3% | 4.4% | -406.4% |
| FCF margin | 20.1% | 6.0% | 4.9% | 2.6% | -328.7% |
| SBC / revenue | 5.5% | 7.3% | 10.0% | 11.4% | 65.3% |
| Current ratio | 3.79x | 3.30x | 4.34x | 5.16x | 4.38x |
| Revenue YoY growth | 60.1% | 56.6% | 22.7% | 471.2% | Unavailable |
| Net margin | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% |
| R&D / revenue | 14.3% | 26.4% | 28.2% | 29.7% | 257.6% |
| CapEx / revenue | 0.2% | 0.1% | 0.0% | 0.0% | 1.1% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 33.6% | Unavailable | Unavailable | -1563.0% | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KNSA in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-04-28View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-07-29View SEC filing
10-Q · Filed 2025-04-29View SEC filing
10-K · Filed 2025-02-25View SEC filing
Reconciliation checks needing review
1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.